Do elevated F2-isoprostanes and oxidized LDL indicate oxidative lipid injury and plaque formation?

Biomarkers of oxidative lipid injury

• F2-isoprostanes as systemic indicators: F2-isoprostanes are stable, non-enzymatic products of arachidonic acid peroxidation, serving as the gold-standard biomarker for systemic lipid peroxidation in vivo. For clinical precision, they must be measured using mass spectrometry (GC-MS or LC-MS/MS), as standard ELISA immunoassays often exhibit systematic bias, overestimating concentrations due to antibody cross-reactivity.
• Oxidized LDL as a vascular indicator: Oxidized LDL (oxLDL) represents compartment-specific lipid injury, reflecting localized oxidative modification within circulating low-density lipoprotein particles and the vascular wall.

Pathophysiological mechanisms of plaque formation

• Endothelial dysfunction: Within the arterial intima, oxLDL binds to and activates lectin-like oxidized LDL receptor-1 (LOX-1) on endothelial cells. This pathway triggers reactive oxygen species (ROS) production, depletes nitric oxide, and upregulates adhesion molecules (ICAM-1, VCAM-1) and chemokines (MCP-1).
• Foam cell accumulation: Recruited monocytes differentiate into macrophages, which continuously internalize oxLDL via scavenger receptors (CD36, SR-A, and LOX-1). This unregulated lipid uptake transforms them into foam cells, establishing a pro-inflammatory microenvironment that drives necrotic core progression.
• Clinical implications: Elevated oxLDL serves as a functional driver of vascular disease, predicting the 10-year progression of carotid atherosclerosis and elevated risk of coronary events.

Bottom line

• Elevated F2-isoprostanes and oxLDL are complementary biomarkers of lipid injury; F2-isoprostanes serve as the gold standard for systemic lipid peroxidation, while oxLDL acts as a direct pathogenic driver of atherosclerosis by activating LOX-1, initiating endothelial dysfunction, and promoting macrophage foam cell formation.